{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:45:06Z","timestamp":1792431906628,"version":"4.5.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejpb.2024.114361","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T16:30:40Z","timestamp":1718123440000},"page":"114361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India"],"prefix":"10.1016","volume":"201","author":[{"given":"Kirthiga Devi","family":"S S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Joga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-4028","authenticated-orcid":false,"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114361_b0005","unstructured":"USFDA, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114361_b0010","unstructured":"A.f.R. medicine, Alliance for Regenerative medicine, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4155\/ppa-2022-0001","article-title":"Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting","volume":"11","author":"Sabanis","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejpb.2024.114361_b0020","article-title":"Enhancing cancer immunotherapy: Exploring strategies to target the PD-1\/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape","volume":"114323","author":"Devi","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114361_b0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejpb.2024.114361_b0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.24791","article-title":"Gene therapies for cancer: strategies, challenges and successes","volume":"230","author":"Das","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejpb.2024.114361_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: a race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.ejpb.2024.114361_b0040","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Molecular Therapy-Oncolytics"},{"key":"10.1016\/j.ejpb.2024.114361_b0045","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114361_b0050","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2024.114361_b0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl j Med"},{"key":"10.1016\/j.ejpb.2024.114361_b0060","first-page":"1022","article-title":"Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors","volume":"7","author":"Heiblig","year":"2015","journal-title":"World Journal of Stem Cells"},{"key":"10.1016\/j.ejpb.2024.114361_b0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejpb.2024.114361_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101934","article-title":"Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications","volume":"82","author":"Thanindratarn","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2024.114361_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2478\/ahp-2020-0002","article-title":"A brief history of CAR-T cells: from laboratory to the bedside","volume":"51","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.ejpb.2024.114361_b0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114361_b0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114361_b0090","first-page":"203","article-title":"A graduate-level interdisciplinary curriculum in CAR-T cell therapy","volume":"4","author":"Sterner","year":"2020","journal-title":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes"},{"key":"10.1016\/j.ejpb.2024.114361_b0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13340","article-title":"CD 19 chimeric antigen receptor T cell therapy for haematological malignancies","volume":"169","author":"Ghorashian","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejpb.2024.114361_b0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejpb.2024.114361_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14712598.2017.1322953","article-title":"Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy","volume":"17","author":"Locke","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejpb.2024.114361_b0110","unstructured":"USFDA, Resources Related to Regenerative Medicine Therapies, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0115","unstructured":"USFDA, Establishment of the Office of Therapeutic Products, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0120","unstructured":"USFDA, Regenerative Medicine Fellowship under the Service Fellowship Program for CBER, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0125","unstructured":"USFDA, Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0130","unstructured":"USFDA, OTAT INTERACT Meeting, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0135","unstructured":"USFDA, Fast Track, in, 2018."},{"key":"10.1016\/j.ejpb.2024.114361_b0140","unstructured":"USFDA, Expedited Programs for Serious Conditions \u2013 Drugs and Biologics in, 2014."},{"key":"10.1016\/j.ejpb.2024.114361_b0145","unstructured":"USFDA, CDER Fast Track Designation Requests Received, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0150","unstructured":"USFDA, Breakthrough Therapy, in, 2018."},{"key":"10.1016\/j.ejpb.2024.114361_b0155","unstructured":"USFDA, CDER Breakthrough Therapy Designation Requests Received by Fiscal Year, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0160","unstructured":"USFDA, Regenerative Medicine Advanced Therapy Designation, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0165","unstructured":"USFDA, Cumulative CBER Regenerative Medicine Advanced Therapy (RMAT) Designation Requests Received by Fiscal Year, in, 2024."},{"key":"10.1016\/j.ejpb.2024.114361_b0170","author":"Usfda","year":"2018","journal-title":"Priority Review, in"},{"key":"10.1016\/j.ejpb.2024.114361_b0175","unstructured":"USFDA, Accelerated Approval, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0180","unstructured":"USFDA, CDER Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0185","unstructured":"USFDA, Expanded Access, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0190","unstructured":"USFDA, Rare Pediatric Disease Priority Review Vouchers, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114361_b0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5582\/irdr.2023.01055","article-title":"Vosoritide, a miracle drug, covering unmet need in achondroplasia: A regulatory update","volume":"12","author":"Dushantrao","year":"2023","journal-title":"Intractable & Rare Diseases Research"},{"key":"10.1016\/j.ejpb.2024.114361_b0200","unstructured":"USFDA, 21 CFR Part 316: Orphan Drugs, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0205","unstructured":"USFDA, Orphan Drugs, in, 2012."},{"key":"10.1016\/j.ejpb.2024.114361_b0210","unstructured":"USFDA, 21st Century Cures Act, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0215","unstructured":"USFDA, Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0220","unstructured":"USFDA, Recommendations for Microbial Vectors Used for Gene Therapy, in, 2016."},{"key":"10.1016\/j.ejpb.2024.114361_b0225","unstructured":"USFDA, Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271, in, 2017."},{"key":"10.1016\/j.ejpb.2024.114361_b0230","unstructured":"USFDA, Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0235","unstructured":"USFDA, Long Term Follow-Up After Administration of Human Gene Therapy Products, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0240","unstructured":"USFDA, Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0245","unstructured":"USFDA, Human Gene Therapy for Rare Diseases, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0250","unstructured":"USFDA, Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0255","unstructured":"EMA, REGULATION (EC) No 1394\/2007 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004, in, 2007."},{"key":"10.1016\/j.ejpb.2024.114361_b0260","unstructured":"EMA, Advanced therapy medicinal products: Overview, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0265","unstructured":"EMA, EMA warns against using unproven cell-based therapies, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0270","unstructured":"EMA, Conditional marketing authorisation, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0275","unstructured":"EMA, PRIME: Paving the way for promising medicines for patients, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0280","unstructured":"EMA, PRIME: Priority medicines, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0285","unstructured":"EMA, CAT quarterly highlights and approved ATMPs, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0290","unstructured":"EMA, Compassionate use, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0295","unstructured":"EMA, Accelerated assessment, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0300","unstructured":"EMA, Exceptional circumstances, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0305","unstructured":"EMA, Adaptive pathways, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0310","unstructured":"EMA, REGULATION (EC) No 141\/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products, in, 1999."},{"key":"10.1016\/j.ejpb.2024.114361_b0315","unstructured":"EMA, Procedural advice for orphan medicinal product designation in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0320","unstructured":"EMA, Orphan incentives, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0325","unstructured":"EMA, Guideline On Human Cell-Based Medicinal Products, in, 2008."},{"key":"10.1016\/j.ejpb.2024.114361_b0330","unstructured":"EMA, Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer, (2016)."},{"key":"10.1016\/j.ejpb.2024.114361_b0335","unstructured":"EMA, Guideline on development and manufacture of lentiviral vectors, in, 2005."},{"key":"10.1016\/j.ejpb.2024.114361_b0340","unstructured":"EMA, Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products, in, 2008."},{"key":"10.1016\/j.ejpb.2024.114361_b0345","unstructured":"EMA, Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products, (2008)."},{"key":"10.1016\/j.ejpb.2024.114361_b0350","unstructured":"EMA, Guideline on scientific requirements for the environmental risk assessment of gene-therapy medicinal products, in, 2008."},{"key":"10.1016\/j.ejpb.2024.114361_b0355","unstructured":"EMA, Guideline on follow-up of patients adminstered with gene therapy medicinal products, in, 2010."},{"key":"10.1016\/j.ejpb.2024.114361_b0360","unstructured":"EMA, Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products, in, 2018."},{"key":"10.1016\/j.ejpb.2024.114361_b0365","unstructured":"EMA, Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114361_b0370","unstructured":"EMA, Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114361_b0375","unstructured":"EMA, Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells., in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0380","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s40778-015-0012-6","article-title":"Regulatory landscape of regenerative medicine in Japan","volume":"1","author":"Azuma","year":"2015","journal-title":"Current Stem Cell Reports"},{"key":"10.1016\/j.ejpb.2024.114361_b0385","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cpt.1383","article-title":"A review of the regulatory framework for initiation and acceleration of patient access to innovative medical products in Japan","volume":"106","author":"Matsushita","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114361_b0390","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/cts.12898","article-title":"Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval","volume":"14","author":"Matsushita","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejpb.2024.114361_b0395","unstructured":"PMDA, Reviews, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0400","unstructured":"PMDA, Rolling Reviews in SAKIGAKE and Breakthrough Therapy Designation, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0405","unstructured":"MHLW, Overview of Orphan Drug\/Medical Device Designation System, in, 2009."},{"key":"10.1016\/j.ejpb.2024.114361_b0410","article-title":"Clinical investigations of CAR-T cell therapy for solid tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2024.114361_b0415","unstructured":"EMA, Human cell-based medicinal products - Scientific guideline, in, 2008."},{"key":"10.1016\/j.ejpb.2024.114361_b0420","unstructured":"PMDA, Regenerative Medical Products, in."},{"key":"10.1016\/j.ejpb.2024.114361_b0425","unstructured":"USFDA, Cellular & Gene Therapy Products, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0430","unstructured":"I.C.o.M.R. (ICMR), National Guidelines for Gene Therapy Product Development and Clinical Trials, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114361_b0435","unstructured":"C.D.S.C.O. (CDSCO), New Drugs and Clinical Trials Rules, 2019, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114361_b0440","unstructured":"ClinicalTrials.gov, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0445","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","article-title":"CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape","volume":"26","author":"Pettitt","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2024.114361_b0450","unstructured":"USFDA, Statistical Reviewer - BREYANZI, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0455","unstructured":"USFDA, BREYANZI (lisocabtagene maraleucel), in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0460","unstructured":"EMA, Orphan designation withdrawal assessment report, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0465","unstructured":"EMA, BREYANZI Public Assessment Report, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114361_b0470","unstructured":"EMA, Breyanzi (lisocabtagene maraleucel), in."},{"key":"10.1016\/j.ejpb.2024.114361_b0475","unstructured":"PMDA, Review Report: BREYANZI, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114361_b0480","unstructured":"USFDA, BREYANZI Summary Basis for Regulatory Action, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114361_b0485","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcyt.2018.03.038","article-title":"A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making","volume":"20","author":"Coppens","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejpb.2024.114361_b0490","unstructured":"EMA, Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products, in, 2017."},{"key":"10.1016\/j.ejpb.2024.114361_b0495","unstructured":"C. Corporation, CMC challenges in autologous CAR T products, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114361_b0500","unstructured":"USFDA, Guideline on Preclinical Assessment of Investigational Cellular and Gene Therapy Products, in, 2013."},{"key":"10.1016\/j.ejpb.2024.114361_b0505","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejpb.2024.114361_b0510","unstructured":"USFDA, Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products, in, 2015."},{"key":"10.1016\/j.ejpb.2024.114361_b0515","doi-asserted-by":"crossref","unstructured":"R.M. C\u00e9cile F Rousseau, Dariusz \u015aladowski, Gopalan Narayanan, Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them, Frontiers in medicine, (2018).","DOI":"10.3389\/fmed.2018.00158"},{"key":"10.1016\/j.ejpb.2024.114361_b0520","unstructured":"A.P. Aleksei Titov, Alena Staliarova, Dmitriy Motorin, Emil Bulatov, Oleg Shuvalov, Surinder M Soond, Mauro Piacentini, Gerry Melino, Andrey Zaritskey, Nickolai A Barlev, The biological basis and clinical symptoms of CAR-T therapy-associated toxicites, Cell Death & Disease, (2018)."},{"key":"10.1016\/j.ejpb.2024.114361_b0525","unstructured":"M. Sahlolbei, A. Ahmadieh-Yazdi, M. Rostamipoor, H. Manoochehri, H. Mahaki, H. Tanzadehpanah, N. Kalhor, M. Sheykhhasan, CAR T-Cell Therapy: A New Era in Cancer Immunotherapy, (2024)."},{"key":"10.1016\/j.ejpb.2024.114361_b0530","article-title":"Cancer incidence estimates for 2022 & projection for 2025: result from national cancer registry programme, India","author":"Sathishkumar","year":"2023","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejpb.2024.114361_b0535","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(14)70115-9","article-title":"The growing burden of cancer in India: epidemiology and social context","volume":"15","author":"Mallath","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejpb.2024.114361_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jpgm.JPGM_391_18","article-title":"Access to hematopoietic stem-cell transplantation in India","volume":"65","author":"Kulkarni","year":"2019","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.ejpb.2024.114361_b0545","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcyt.2021.09.007","article-title":"CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes","volume":"24","author":"Ravindranath","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejpb.2024.114361_b0550","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/1535-7163.MCT-20-0476","article-title":"Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells","volume":"20","author":"Dwivedi","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2024.114361_b0555","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/EDBK_100028","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access","volume":"41","author":"Leighl","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ejpb.2024.114361_b0560","unstructured":"G. Healthcare, Few contract manufacturing sites exist to supply world\u2019s viral vectors, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114361_b0565","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/picr.PICR_189_20","article-title":"National guidelines for gene therapy product (2019): A road-map to gene therapy products development and clinical trials","volume":"12","author":"Sivagourounadin","year":"2021","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.ejpb.2024.114361_b0570","unstructured":"P. Sahoo, CAR T-cell therapy trials for cancer treatment begin in Mumbai, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114361_b0575","unstructured":"BIRAC, Projects Supported by BIRAC under NBM, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0580","doi-asserted-by":"crossref","unstructured":"R.C. Annu Uppal, Narendra Chirmule, Shashwati Basak & Fouad Atouf, Overcoming challenges to CAR-T cell therapies in India, (2023).","DOI":"10.18609\/cgti.2023.029"},{"key":"10.1016\/j.ejpb.2024.114361_b0585","unstructured":"Department of Biotechnology supported First CAR-T cell therapy conducted at ACTREC, Tata Hospital in Mumbai, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114361_b0590","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2023-185507","article-title":"High efficacy and excellent safety profile of actalycabtagene autoleucel, a humanized CD19 CAR-T product in r\/r B-cell malignancies: a phase ii pivotal trial","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2024.114361_b0595","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","article-title":"Cutting-edge CAR-T cancer therapy is now made in India-at one-tenth the cost","volume":"627","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2024.114361_b0600","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114361_b0605","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejpb.2024.114361_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101186","article-title":"Long-term stability of clinical-grade lentiviral vectors for cell therapy","volume":"32","author":"Jadlowsky","year":"2024","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"10.1016\/j.ejpb.2024.114361_b0615","doi-asserted-by":"crossref","DOI":"10.1177\/2155179018822781","article-title":"Approval of first CAR-Ts: have we solved all hurdles for ATMPs?","volume":"11","author":"Seimetz","year":"2019","journal-title":"Cell Medicine"},{"key":"10.1016\/j.ejpb.2024.114361_b0620","unstructured":"USFDA, FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies, in, 2023."},{"key":"10.1016\/j.ejpb.2024.114361_b0625","unstructured":"FDA, FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies, in, 2024."},{"key":"10.1016\/j.ejpb.2024.114361_b0630","first-page":"1","article-title":"CAR T therapies in multiple myeloma: unleashing the future","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejpb.2024.114361_b0635","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/0955757042000203632","article-title":"Globalisation or \u2018glocalisation\u2019?","volume":"17","author":"Swyngedouw","year":"2004","journal-title":"Networks, Territories and Rescaling, Cambridge Review of International Affairs"},{"key":"10.1016\/j.ejpb.2024.114361_b0640","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.beha.2018.01.002","article-title":"Gmp CAR-T Cell Production","volume":"31","author":"Gee","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ejpb.2024.114361_b0645","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.ejpb.2024.114361_b0650","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ejpb.2024.114361_b0655","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000495772","article-title":"Functionality and cell senescence of CD4\/CD8-selected CD20 CAR T cells manufactured using the automated CliniMACS Prodigy\u00ae platform","volume":"46","author":"Aleksandrova","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.ejpb.2024.114361_b0660","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Molecular Therapy-Oncolytics"},{"key":"10.1016\/j.ejpb.2024.114361_b0665","first-page":"136","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials, Molecular Therapy-Methods & Clinical","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Development"},{"key":"10.1016\/j.ejpb.2024.114361_b0670","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2024.114361_b0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02510-7","article-title":"A deep insight into CRISPR\/Cas9 application in CAR-T cell-based tumor immunotherapies","volume":"12","author":"Razeghian","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ejpb.2024.114361_b0680","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Advances in Cell and Gene Therapy"},{"key":"10.1016\/j.ejpb.2024.114361_b0685","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejpb.2024.114361_b0690","article-title":"Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy","volume":"2313226","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejpb.2024.114361_b0695","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114361_b0700","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4155\/ppa-2021-0029","article-title":"Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer","volume":"11","author":"Joga","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejpb.2024.114361_b0705","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4155\/ppa-2022-0046","article-title":"Photoresponsive liposomes: an alternative of ELISA for the detection of low quantities of target substances","volume":"12","author":"Joga","year":"2023","journal-title":"Pharm. Pat. Anal."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:53:56Z","timestamp":1729173236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":141,"alternative-id":["S0939641124001875"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114361","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114361"}}